Tissue Repair Limited (ASX:TRP) Announces Q4 2024 Progress and Financial Results
Tissue Repair (ASX:TRP) reports strong Q4 2024 progress in drug trials and a 35% increase in TR Pro+® sales.
Category: Healthcare
HITIQ Limited (ASX:HIQ) Converts $1.6m Notes to Shares and Secures New Advisory Mandate
HITIQ Limited (ASX:HIQ) converts $1.6m in notes into shares and secures a new advisory mandate to enhance US investor relations.
Chimeric Therapeutics Limited (ASX:CHM) Reports Q4 Activities
Chimeric Therapeutics (ASX:CHM) advances clinical trials, secures $5M in funding, and appoints Dr Rebecca McQualter as CEO in Q4 report.
Arovella Therapeutics Limited (ASX:ALA) Raises $20M to Fund Phase 1 Clinical Trials
Arovella Therapeutics (ASX:ALA) secures $20 million placement, fully funding Phase 1 trials for ALA-101 and advancing its cancer therapy pipeline.
Vectus Biosystems Limited (ASX:VBS) Releases December 2024 Quarterly Activities Report
Vectus Biosystems Limited (ASX:VBS) releases its December 2024 Quarterly Activities Report, detailing clinical trial progress and a strong financial position.
Opthea Limited (ASX:OPT) Releases Q2 FY25 Activity Report
Opthea Limited (ASX:OPT) releases Q2 FY25 Activity Report, detailing advancements in Phase 3 trials and financial developments including a R&D tax incentive.
Althea Group Holdings (ASX:AGH) Reports Quarterly Results
Althea Group Holdings (ASX:AGH) announces $9.01 million in Q2 receipts, with ongoing governance improvements and operational strides in cannabis.
Superior Resources Limited (ASX:SPQ) Reports Significant Progress in Q4 Activities
Superior Resources Limited (ASX:SPQ) reports notable progress in exploration, including new gold zones and funding for drilling initiatives.
Nova Eye Medical Limited (ASX:EYE) Completes $6.6 Million Placement
Nova Eye Medical Limited (ASX:EYE) secures $6.6 million to expand operations and enhance growth in the ophthalmic technology sector.
Nova Eye Medical Limited (ASX:EYE) Announces Capital Raise to Drive Growth
Nova Eye Medical (ASX:EYE) announces a capital raise to bolster its financial stability and operational growth amid increasing demand in the ophthalmology sector.